Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Melanoma 71Neoplasms 28Neoplasm Metastasis 15Colorectal Neoplasms 9Multiple Myeloma 6Thyroid Neoplasms 5Skin Neoplasms 5Lymphoma, Non-Hodgkin 5Carcinoma, Non-Small-Cell Lung 5Thyroid Cancer, Papillary 4Leukemia, Hairy Cell 4Hematologic Neoplasms 4Sarcoma 3Pancreatic Neoplasms 3Glioma 3Breast Neoplasms 3Wilms Tumor 2Thyroid Carcinoma, Anaplastic 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Recurrence 2Prostatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasms by Site 2Neoplasms by Histologic Type 2Lymphoma 2

Interventions

Bevacizumab 19Capecitabine 15Oxaliplatin 11Irinotecan 11Cetuximab 11Fluorouracil 10Leucovorin 8aflibercept 7Panitumumab 6trifluridine tipiracil drug combination 4Nivolumab 4sintilimab 3regorafenib 3Ipilimumab 3Vemurafenib 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2HMPL-013 2Folfox protocol 2Drug Therapy 2tremelimumab 1spartalizumab 1raltitrexed 1pembrolizumab 1monoclonal antibody YYB-101 1masitinib 1irinotecan sucrosofate 1glucopyranosyl lipid-A 1folfirinox 1durvalumab 1camrelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Colorectal Cancer Metastatic × Vemurafenib × Clear all
NCT06008119 2025-09-18

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Shanghai Kechow Pharma, Inc.

Phase 3 Recruiting
165 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

NCT04790448 2023-02-15

Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer

Sun Yat-sen University

Phase 1/2 Completed
37 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡